Anti-hPD-L1-mIgG1

Human PD-L1 antibody - Mouse IgG1

ABOUT

Human PD-L1 mAb for murine studies

Anti-hPD-L1-mIgG1 features a variable region equivalent to that of Atezolizumab, a therapeutic monoclonal antibody (mAb) that targets PD-L1, blocking the interaction with its receptor PD-1. Atezolizumab (formerly known as MPDL3280A) is a fully-humanized IgG1 mAb with a modified Fc region designed to limit antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [1, 2]. It contains an N298A mutation that eliminates its ability to bind to human Fcγ receptors. In contrast to nivolumab, a therapeutic mAb that targets only human PD-1, Atezolizumab targets both human and mouse PD-L1. 

To enable studies in mice,  InvivoGen's Anti-hPD-L1-mIgG1 contains the constant region of mouse IgG1; an isotype exhibiting low CDC and no ADCC. Anti-hPD-L1-mIgG1 was generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography with protein G.

 

Anti-hPD-L1-mIgG1 InvivoFit™ is specifically designed for mouse studies:

  • Contains a mouse IgG1 Fc domain to prevent ADAs (anti-drug-antibodies)
  • Guaranteed sterile
  • Endotoxin level
  • Low aggregation, < 5%
  • No preservative
  • Binding validated by flow cytometry using EL4 cells expressing membrane-bound mouse PD-L1
 

The terms “Atezolizumab” and “MPDL3280A” are only used as references. Anti-hPD-L1-mIgG1 is not a pharmaceutical biosimilar of Atezolizumab. It has not been developed nor approved by Atezolizumab owner(s), and is not intended for any therapeutic or diagnostic use in humans or animals.

 

References:

1. Spigel D. et al., 2013. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [ASCO abstract 8008]. J Clin Oncol. 31(15)(suppl).
2. Herbst RS. et al., 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515(7528):563-7.

All products are for internal research use only, and not for human or veterinary use.

InvivoFit™

InvivoFit™ is a high-quality standard specifically adapted for in vivo studies. 
InvivoFit™ products are filter-sterilized (0.2 µm) and filled under strict aseptic conditions in a clean room. The level of bacterial contaminants (endotoxins and lipoproteins) in each lot is verified using a LAL assay and a TLR2 and TLR4 reporter assay

SPECIFICATIONS

Specifications

Applications

Flow cytometry

Isotype
mIgG1
Source
CHO cells
Purification
Protein G
Formulation buffer

Sodium phosphate buffer with glycine, saccharose and stabilizing agents

Preservative
Azide-free
Reconstitution buffer
Sterile water
Tested applications

Binding validated by flow cytometry using EL4 cells expressing membrane-bound mouse PD-L1

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hPD-L1-mIgG1
  • Cat code: 
    hpdl1-mab9
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20°C

    Caution:

    • Avoid repeated freeze-thaw cycles

DOCUMENTS

Documents

Anti-hPD-L1-mIgG1

Technical Data Sheet

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?